CompanyGraph
Sonova Holding AG
SOON · SIX Swiss · Switzerland
Price data from its 0QPY listing on LSE
sonova.comFinancials as of FY2026
At a glance
- Depends onMidstream position: 6 outgoing, 8 incoming connections
- ScaleMarket cap is $17.8B, above the global median of $1.15B
- PositionReturn on equity is 20.5%, higher than 95% of its Medical Devices peers (median 3%)
- Interpretations2 currently firing — 2
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
1.94%Above 5Y avg (1.67%)
Annual Rate
CHF 4.70Paid annual
Payout Ratio
48.8%Sustainable
Consecutive Growth
1 yr
Paying Dividends
20 yr
Payback Period
51.5 yr
Last Ex-Dividend
Jun 19, 2026
Last Payment
Jun 17, 2024
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
14.46BCHF17.80B · vs all stocks (USD)
Trailing P/E
27.01xvs Medical Devices peers
Revenue (TTM)
3.61BCHF4.44B · vs all stocks (USD)
Profit Margin
11.94%vs Medical Devices peers
Beta
1.10xvs all stocks
52-Week Change
3.87%vs all stocks
Market Capitalization
14.46BCHF17.80B · vs all stocks (USD)
Enterprise Value
15.21BCHF18.72B · vs all stocks (USD)
Trailing P/E
27.01xvs Medical Devices peers
Forward P/E
20.63xvs Medical Devices peers
Price to Sales (TTM)
4.01xvs Medical Devices peers
Price to Book (MRQ)
5.53xvs Medical Devices peers
Enterprise to Revenue
4.22xvs Medical Devices peers
Enterprise to EBITDA
18.07xvs Medical Devices peers
Profit Margin
11.94%vs Medical Devices peers
Operating Margin
19.55%vs Medical Devices peers
Return on Assets (TTM)
7.63%vs Medical Devices peers
Return on Equity (TTM)
20.52%vs Medical Devices peers
Revenue (TTM)
3.61BCHF4.44B · vs all stocks (USD)
Revenue per Share (TTM)
60.53CHFUpdated Aug 19, 2026Gross Profit (TTM)
2.66BCHF3.27B · vs all stocks (USD)
EBITDA (TTM)
930.70MCHF1.15B · vs all stocks (USD)
Net Income (TTM)
537.10MCHF661.16M · vs all stocks (USD)
Operating Cash Flow (TTM)
707.50MCHF870.92M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
346.06MCHF426.00M · vs all stocks (USD)
Trailing Annual Dividend Rate
4.70CHFUpdated Aug 19, 2026Trailing Annual Dividend Yield
1.94%vs all stocks
5-Year Average Dividend Yield
1.67%vs all stocks
Payout Ratio
48.83%vs Medical Devices peers
Minority Interest (Equity)
22.00MCHFFY2026 · Mar 31, 2026Revenue
3.61BCHFFY2026 · Mar 31, 2026Cost of Goods Sold
947.60MCHFFY2026 · Mar 31, 2026Gross Profit
2.66BCHFFY2026 · Mar 31, 2026Operating Income
675.90MCHF832.02M · vs all stocks (USD)
Pre-tax Income
641.70MCHFFY2026 · Mar 31, 2026Income Tax Expense
95.70MCHFFY2026 · Mar 31, 2026Net Income
439.50MCHFFY2026 · Mar 31, 2026EBIT
670.40MCHFFY2026 · Mar 31, 2026EBITDA (Income Statement)
930.70MCHFFY2026 · Mar 31, 2026Research & Development
217.70MCHFFY2026 · Mar 31, 2026Selling, General & Administrative
1.74BCHFFY2026 · Mar 31, 2026Other Operating Expenses
25.90MCHFFY2026 · Mar 31, 2026Non-operating Interest Income
6.20MCHFFY2026 · Mar 31, 2026Non-operating Interest Expense
28.70MCHFFY2026 · Mar 31, 2026Minority Interests (P&L)
-8.90MCHFFY2026 · Mar 31, 2026Preferred Stock Dividends
0.00CHFFY2026 · Mar 31, 2026Operating Cash Flow
685.10MCHFFY2026 · Mar 31, 2026Free Cash Flow
604.40MCHFFY2026 · Mar 31, 2026Cash & Cash Equivalents (End of Period)
738.70MCHFFY2026 · Mar 31, 2026Starting Profit (CF Statement)
641.70MCHFFY2026 · Mar 31, 2026Stock-based Compensation
19.30MCHFFY2026 · Mar 31, 2026Other Non-cash Items
43.10MCHFFY2026 · Mar 31, 2026Change in Accounts Receivable (CF)
-50.00MCHFFY2026 · Mar 31, 2026Change in Other Assets/Liabilities
31.00MCHFFY2026 · Mar 31, 2026Capital Expenditures
-80.70MCHFFY2026 · Mar 31, 2026Net Intangibles (CF)
-21.30MCHFFY2026 · Mar 31, 2026Net Acquisitions
-45.50MCHFFY2026 · Mar 31, 2026Purchase of Investments
-102.00MCHFFY2026 · Mar 31, 2026Sale of Investments
63.20MCHFFY2026 · Mar 31, 2026Net Investing Cash Flow
-165.00MCHFFY2026 · Mar 31, 2026Long-term Debt Issuance
360.20MCHFFY2026 · Mar 31, 2026Long-term Debt Payments
-386.90MCHFFY2026 · Mar 31, 2026Common Stock Repurchase
-63.10MCHFFY2026 · Mar 31, 2026Common Dividends Paid
-262.30MCHFFY2026 · Mar 31, 2026Net Financing Cash Flow
-346.40MCHFFY2026 · Mar 31, 2026Shares Outstanding
59.40MSharesUpdated Aug 19, 2026Float Shares
59.22MSharesUpdated Aug 19, 2026% Held by Insiders
17.50%vs all stocks
% Held by Institutions
48.62%vs all stocks
Total Cash (MRQ)
722.00MCHF888.77M · vs all stocks (USD)
Total Cash per Share (MRQ)
12.15CHFUpdated Aug 19, 2026Total Debt (MRQ)
1.71BCHF2.11B · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.6494xvs Medical Devices peers
Current Ratio (MRQ)
1.75xvs Medical Devices peers
Book Value per Share (MRQ)
44.00CHFUpdated Aug 19, 2026Total Assets
5.63BCHF6.93B · vs all stocks (USD)
Total Current Assets
2.08BCHFFY2026 · Mar 31, 2026Total Liabilities
2.99BCHFFY2026 · Mar 31, 2026Total Non-current Assets
3.55BCHFFY2026 · Mar 31, 2026Total Non-current Liabilities
1.80BCHFFY2026 · Mar 31, 2026Total Current Liabilities
1.19BCHFFY2026 · Mar 31, 2026Cash
541.70MCHFFY2026 · Mar 31, 2026Cash Equivalents
180.30MCHFFY2026 · Mar 31, 2026Cash & Cash Equivalents
722.00MCHFFY2026 · Mar 31, 2026Other Short-term Investments
100.00KCHFFY2026 · Mar 31, 2026Accounts Receivable
527.30MCHFFY2026 · Mar 31, 2026Inventory
381.00MCHFFY2026 · Mar 31, 2026Accounts Payable
177.10MCHFFY2026 · Mar 31, 2026Short-term Debt
186.30MCHFFY2026 · Mar 31, 2026Other Current Liabilities
200.00KCHFFY2026 · Mar 31, 2026Long-term Debt
1.53BCHFFY2026 · Mar 31, 2026Other Non-current Liabilities
1.30MCHFFY2026 · Mar 31, 2026Common Stock (Book)
3.00MCHFFY2026 · Mar 31, 2026Retained Earnings
2.66BCHFFY2026 · Mar 31, 2026Total Shareholders' Equity
2.64BCHF3.24B · vs all stocks (USD)
Treasury Stock
45.60MCHFFY2026 · Mar 31, 202652-Week Low
163.00CHFUpdated Aug 19, 202652-Week High
245.70CHFUpdated Aug 19, 202652-Week Change
3.87%vs all stocks
Beta
1.10xvs all stocks
50-Day MA
210.58CHFUpdated Aug 19, 2026200-Day MA
201.00CHFUpdated Aug 19, 2026Avg 10-Day Volume
146.95KSharesUpdated Aug 19, 2026Avg 30-Day Volume
141.75KSharesUpdated Aug 19, 2026Diluted EPS (TTM)
9.01CHFUpdated Aug 19, 20262 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company use capital?
FCF Ratios Elevated
Its free cash flow is large next to assets and equity, and more of its operating cash reaches it than in its industry.
Reads
Industry-Benchmarked ROA and Margin Elevated
Returns and margins have sat in the top of its industry across five years.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Return on equity is 20.5%, higher than 95% of its Medical Devices peers (median 3%)Significant
Return on equity: 0.21Industry median: 0.03Industry P95: 0.17Peers compared: 102
Financial Health
Altman Z-Score 4.78: safe zoneNotable
Altman Z-Score: 4.78
Supply Chain
Midstream position: 6 outgoing, 8 incoming connectionsNotable
Outgoing: 6.00Incoming: 8.00
High connectivity hub: 14 industry connectionsNotable
Total Connections: 14.00
Scale
Market cap is $17.8B, above the global median of $1.15BNotable
Market cap (USD): 17,798,837,722.301Global Median: 1,146,734,693.424
Revenue is $4.44B, above the global median of $520.53MNotable
Revenue (USD): 4,438,790,821.391Global Median: 520,528,949.311
Levered free cash flow is $426M, above the global median of $16.24MNotable
Levered free cash flow (USD): 425,996,011.326Global Median: 16,239,329.704
Companies that share the same coordination system — how they create, deliver, or capture value.
Zimmer Biomet Holdings, Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Sichuan Biokin Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Neurocrine Biosciences Inc.
Tier 1ProductionApproval-Gated PipelineRule
Torrent Pharmaceuticals Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Sino Biopharmaceutical Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
BridgeBio Pharma, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Ipsen S.A.
Tier 1ProductionApproval-Gated PipelineRule
Viatris Inc.
Tier 1ProductionApproval-Gated PipelineRule
Jazz Pharmaceuticals plc
Tier 1ProductionApproval-Gated PipelineRuleRisk
ALTEOGEN Inc.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
XPEL, Inc.
2 interpretationsFCF Ratios ElevatedIndustry-Benchmarked ROA and Margin Elevated
Spirax Group plc
2 interpretationsFCF Ratios ElevatedIndustry-Benchmarked ROA and Margin Elevated
Coloplast A/S Class B
2 interpretationsFCF Ratios ElevatedIndustry-Benchmarked ROA and Margin Elevated